egnant women referred to Ayatollah Rouhani Hospital in Babol from 2017 to 2019 (a historical cohort study)

Document Type : Original Article

Authors

1 PhD Student in Reproductive Health, Student Research Committee, School of Nursing and Midwifery, Shahroud University of Medical Sciences, Shahroud, Iran. Clinical Research Development Unit of Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran.

2 Professor, Department of Obstetrics and Gynecology, Reproductive Health and Infertility Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.

3 M.Sc. of Midwifery, Clinical Research Development Unit of Rouhani Hospital, School of Nursing and Midwifery, Babol University of Medical Sciences, Babol, Iran.

4 Assistant Professor, Department of Biostatistics, School of Public Health, Shahroud University of Medical Sciences, Shahroud, Iran.

5 Professor, Department of Reproductive Health, School of Nursing and Midwifery, Shahroud University of Medical Sciences, Shahroud, Iran.

Abstract

Introduction: Drug addiction causes complications such as preterm delivery, miscarriage, intrauterine growth retardation, prenatal mortality, placental abruption, preeclampsia, premature rupture of membranes, increased cesarean section and congenital anomalies. Therefore, this study was performed aimed to investigate the prevalence of substance abuse and pregnancy outcomes.
Methods: This study was conducted in two stages, initially a cross-sectional study was performed in all pregnant women referred to the maternity ward of Ayatollah Rouhani Hospital in Babol from April 2017 to March 2019. Then, a historical cohort study was conducted in which the subjects were divided into two groups: 112 addicted pregnant women and 224 non-addicted pregnant women. Data collection tool was a researcher-made checklist including: demographic information, maternal complications, and fetal-neonatal complications. Data were analyzed using SPSS software (version 21) and T-test and Chi-square test. P<0.05 was considered statistically significant.
Results: The prevalence of addiction was 1.66% among 6713 pregnant women during these three years. Maternal, fetal and neonatal complications showed a significant increase among addicted mothers compared to the control group (P = 0.0001). Premature rupture of membranes in 44 women (39.28%) and preterm delivery in 32 (28.57%) were the most common complications. The chance of premature rupture of the amniotic sac was 9.09 times with a 95% confidence interval (0.058-0.211) and the chance of preterm delivery was 5 times higher with a 95% confidence interval (0.107-0.388) in addicted mothers. The chance of respiratory distress in infants born to addicted mothers was 10 times higher with a 95% confidence interval (0.058-0.227).
Conclusion: Addiction during pregnancy is associated with many maternal, fetal and neonatal complications, so it is recommended that a comprehensive and specific program be performed for diagnostic, treatment and rehabilitation measures, especially to reduce the damage caused by addiction for women.

Keywords

References

  1. Naghibi KH, Attari A. Diagnosis and treatment of drug dependency. Esfehan: University of Medical Sciences; 2004.
  2. publication UN. World Drug Report 2021 [Available from: https://www.unodc.org/res/wdr2021/field/WDR21_Booklet_3.pdf.
  3. Rostam-Abadi Y, Gholami J, Noroozi A, Ansari M, Baheshmat S, Hamzehzadeh M, et al. Public health risks associated with methadone in Iran: A systematic review and meta-analysis. International Journal of Drug Policy 2022; 100:103529.
  4. Ghorbani M, Ansari Talebi S. A review of two decades of research on studies of the prevalence of women’s addiction in Iran. Social Health and Addiction 2016; 3(9):61-90.
  5. Masoumi Z, Shayan A, Azizi S, Sadeghian A. Incidence of complications among infants born from addicted mothers in Fatemieh hospital in Shahroud City, Iran. Journal of Biostatistics and Epidemiology 2018; 4(1):29-4.
  6. World Drug Report; 2018 [Available from: https://www.unodc.org/wdr2018/index.html.
  7. Greenfield SF, Pettinati HM, O’Malley S, Randall PK, Randall CL. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study. Alcoholism: Clinical and Experimental Research 2010; 34(10):1803-12.
  8. Gargari SS, Fallahian M, Haghighi L, Hosseinnezhad-Yazdi M, Dashti E, Dolan K. Maternal and neonatal complications of substance abuse in Iranian pregnant women. Acta Medica Iranica 2012: 411-6.
  9. Salari Z, Mirzaei F, Mehran M. Evaluation of relationship between opioid addiction and placental abruption; 2007.
  10. Grella CE, Hser YI, Huang YC. Mothers in substance abuse treatment: Differences in characteristics based on involvement with child welfare services. Child abuse & neglect 2006; 30(1):55-73.
  11. Vavrinkova B, Binder T, Vitkova I, Zivný J. Placental and umbilical cord changes in drug-addicted women. Ceska gynekologie 2001; 66(5):345-9.
  12. Fanaei H, Riki F, Khayat S, Bornavard M. Brain-derived neurotrophic factor and nerve growth factor concentrations in maternal and umbilical cord blood of opium-addicted mothers. Int J Dev Neurosci 2020; 80(7):594-600.
  13. Keegan J, Parva M, Finnegan M, Gerson A, Belden M. Addiction in pregnancy. J Addict Dis 2010; 29(2):175-91.
  14. Kopecky EA, Ryan ML, Barrett JF, Seaward PG, Ryan G, Koren G, et al. Fetal response to maternally administered morphine. American Journal of Obstetrics and Gynecology 2000; 183(2):424-30.
  15. Salihu HM, Salemi JL, Aggarwal A, Steele BF, Pepper RC, Mogos MF, et al. Opioid drug use and acute cardiac events among pregnant women in the United States. The American Journal of Medicine 2018; 131(1):64-71.
  16. Kuczkowski KM. The effects of drug abuse on pregnancy. Current Opinion in Obstetrics and Gynecology 2007; 19(6):578-85.
  17. Tsakiridis I, Oikonomidou AC, Bakaloudi DR, Dagklis T, Papazisis G, Chourdakis M. Substance Use During Pregnancy: A Comparative Review of Major Guidelines. Obstetrical & Gynecological Survey 2021; 76(10):634-43.
  18. Cook JL, Green CR, de la Ronde S, Dell CA, Graves L, Morgan L, et al. Screening and management of substance use in pregnancy: a review. Journal of Obstetrics and Gynaecology Canada 2017; 39(10):897-905.
  19. Aghamohamadi D, Gol MK. An investigation into the effects of magnesium sulfate on the complications of succinylcholine administration in nulliparous women undergoing elective cesarean section: A double-blind clinical trial. International Journal of Women's Health and Reproduction Sciences 2019; 7(4):520-5.
  20. Charlotte W, Loshak H, Dulong C. Withdrawal Management and Treatment of Crystal Methamphetamine Addiction in Pregnancy: A Review of Clinical Effectiveness and Guidelines. Canadian Agency for Drugs and Technologies in Health, Ottawa (ON); 2019.
  21. de Angelis C, Nardone A, Garifalos F, Pivonello C, Sansone A, Conforti A, et al. Smoke, alcohol and drug addiction and female fertility. Reproductive Biology and Endocrinology 2020; 18(1):1-26.
  22. Stone R. Pregnant women and substance use: fear, stigma, and barriers to care. Health & Justice 2015; 3(1):1-5.
  23. Khajedaluee M, Dadgar Moghadam M. Maternal substance abuse and the child's addiction during adolescence and young adulthood. Iran J Obstet, Gynecol Infertil 2013; 16(52):1-7.
  24. Ramezanzadeh F, Tavafian S, Vahdaninia M, Shariat M, Montazeri A. Maternal and fetal outcomes of narcotic substance abuse, cigarette smoking, and unsafe drugs. Hakim Res J 2007; 10(3):9-16.
  25. Torshizi M, Saadatjoo S, Farabi M. Prevalence of narcotic substance abuse and the maternal and fetal outcomes in pregnant women. Journal of Jahrom University of Medical Sciences 2011;9(3):14-9.
  26. Peyrovi T, Solaeymanirad J. Effect of long term addiction with morphine on fetal rat development. Medical Journal of Tabriz University of Medical Sciences 2002; 35(52):21-25.
  27. Hoang T, Czuzoj-Shulman N, Abenhaim HA. Pregnancy outcome among women with drug dependence: A population-based cohort study of 14 million births. Journal of Gynecology Obstetrics and Human Reproduction 2020; 49(7):101741.
  28. Vucinovic M, Roje D, Vučnović Z, Capkun V, Bucat M, Banović I. Maternal and neonatal effects of substance abuse during pregnancy: our ten-year experience. Yonsei medical journal 2008; 49(5):705-13.
  29. Gabrhelík R, Skurtveit S, Nechanská B, Handal M, Mahic M, Mravčík V. Prenatal methamphetamine exposure and adverse neonatal outcomes: a nationwide cohort study. European Addiction Research 2021; 27(2):97-106.
  30. Sharifian J, Jahanian M, Tavassoli F, Tavassoli S, AfzalAghaee M, Afshari R, et al. The fate of motherhood, fetuses and neonates in drug addicted pregnant women. SSU_Journals 2011; 19(2):183-91.
  31. Leventhal JL, Maida Taylor MD, Sadock V, Schwarz PJ, Arnon SS. Alerts, Notices, and Case Reports. The Western Journal of Medicine 2010; 156(2):116-132.
  32. Kalaitzopoulos DR, Chatzistergiou K, Amylidi AL, Kokkinidis DG, Goulis DG. Effect of methamphetamine hydrochloride on pregnancy outcome: a systematic review and meta-analysis. Journal of addiction medicine 2018; 12(3):220-6.
  33. Thaithumyanon P, Limpongsanurak S, Praisuwanna P, Punnahitanon S. Perinatal effects of amphetamine and heroin use during pregnancy on the mother and infant. Journal-Medical Association of Thailand 2005; 88(11):1506-13.
  34. Neves AR, Neves F, Santos Silva I, Almeida MD, Monteiro P. Mode of Delivery in Drug-Dependent Pregnant Women: A Case Control Study. Journal of Pregnancy 2017; 2017.
The Iranian Journal of Obstetrics, Gynecology and Infertility
Volume 25, Issue 4
June 2022
Pages 43-50

Files

Share

How to cite

Statistics